Poster: AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

Keith W. Pratz,Mohamad Cherry,Nikolai A. Podoltsev,Jessica K. Altman,Alexander E. Perl,Brenda W. Cooper,Joseph G. Jurcic,Tara L. Lin,Gary J. Schiller,Ruishan Wu,Jason E. Hill,Stanley C. Gill,Angela James,Elizabeth Shima Rich,Nahla Hasabou,Mark J. Levis

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览12

暂无评分

摘要

Gilteritinib plus induction and consolidation chemotherapy was well tolerated and resulted in CR, FLT3-ITD clearance, and long-term survival in patients with ND FLT3 AML, supporting ongoing randomized trials testing this approach against current standards.

查看译文

关键词

AML,acute myeloid leukemia,FLT3, gilteritinib,clinical response,adverse events,Phase I

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要